CAMBRIDGE, Mass.--(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis. “This research grant will facilitate the study of the epigenetic control of inflammation, an area of active research at Constellation, in the context of a disease for which the treatment options are very limited,” commented Jose Lora, Ph.D., executive director of preclinical sciences at Constellation.
Help employers find you! Check out all the jobs and post your resume.
